IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression Recurrent pathogenic mutations in IDH1 and IDH2 at the conserved amino acid sites IDH1-R132, IDH2-R140 and IDH2-R172 occur in~20% of patients with acute myeloid leukemia (AML). 1 A recent analysis of AML patients at our institution identified IDH1/2 mutations in 20% (n = 167) of 826 AML patients, with IDH1/2 mutations occurring most frequently in the setting of diploid karyotype or other intermediate-risk cytogenetics, particularly trisomy 8 (77 vs 53%, Po 0.0005). AML patients with IDH1/2 mutations were overall less likely to have a diagnosis of therapyrelated AML (8 vs 17%, P = 0.003). 2 Compared with their frequency in AML, IDH1/2 mutations are less common in myelodysplastic syndromes (MDS), occurring iñ 5% of MDS patients, although an incidence as high as 12% has been reported. [3] [4] [5] [6] [7] [8] Although IDH1/2 mutations are thought to represent early 'driver' events in leukemogenesis with mutational stability over time, reports of IDH1/2 acquisition at the time of leukemic transformation in patients with myeloproliferative neoplasms and MDS have been described. 3, 9, 10 The purpose of this analysis is to evaluate the overall prevalence of IDH1/2 mutations in MDS patients treated at our institution, as well as determine the incidence and frequency of IDH1/2 mutations identified at the time of leukemic transformation in MDS patients.
Eligible patients comprised all adults with histologically confirmed MDS treated at MD Anderson Cancer Center from January 2010 to January 2015. A total of 1042 MDS patients with known IDH1 and IDH2 status were included. From January 2010 to September 2012, IDH1/2 molecular analysis was performed by high-resolution melting curve analysis followed by Sanger sequencing confirmation (analytical sensitivity: 10-20%) as has been previously described. 11 Beginning in September 2012, IDH1/2 testing was performed within a Clinical Laboratory Improvements Ammendments-certified next-generation sequencing platform (analytical sensitivity: 2.5-5%). Statistical analyses were conducted in Statistica v12.0 (StatSoft Inc, Tulsa, OK, USA) and significance defined as P o0.05. Overall survival (OS) was measured as the time from presentation to date of death or last follow-up, and progression-free survival from presentation to date of death, last follow-up, or date of progression to AML. Informed consent was obtained following institutional guidelines and in accordance with the Declaration of Helsinki.
Of the 1042 MDS patients, 60 patients (5.7%) had IDH1/2 mutations identified. Specifically, 17 patients (1.6%) were IDH1-R132 mutated and 43 patients (4.1%) had IDH2-R140 (n = 42) or IDH2-R172 (n = 1) mutations, respectively. The clinicopathological characteristics of patients with and without IDH1/2 mutations are shown in Table 1 . Within this cohort, 701 patients (67%) were untreated and 341 (33%) had received systemic MDS therapy before presentation. MDS patients with IDH1/2 mutations had a lower absolute neutrophil count (1.15 × 10 9 /l vs 1.71 × 10 9 /l, P = 0.02), higher bone marrow blast percentage (6 vs 4%, P = 0.001), and a trend for higher platelet counts (99 × 10 9 /l vs 75 × 10 9 /l, P = 0.07). Of the 60 IDH1/2 mutations, 17 (28%) were present in the very low or low-risk IPSS-R groups, 15 (25%) intermediate, and 27 (45%) in the high or very-high IPSS-R prognostic score categories ( 12 Only 5% of IDH1/2-mutated patients had chromosome 7 abnormalities or complex cytogenetics, compared to 14% of IDH wild-type patients (Table 1) .
At presentation, IDH1/2-mutated patients had higher bone marrow blast percentage than IDH wild-type patients (6 vs 4%, P = 0.001) and were more frequently classified as RAEB-1 or RAEB2 morphology. By WHO classification, 55% of IDH1/2 mutants were classified as RAEB-1 (32%) or RAEB-2 (23%), compared to 42% IDH wild-type (P = 0.051). Additionally, 17% of IDH-mutants were classified as CMML-1 or CMML-2. Interestingly while 10 of the 43 (23%) IDH2 mutations occurred in CMML patients, no IDH1 mutations were detected in CMML patients, suggesting a particular genotype-phenotype correlation with IDH2 mutations and CMML. As SRSF2 mutations, which are not analyzed within our 
73 (7) 6 (10) 2 (12) 4 (9) -7/7q or complex 135 (14) 3 (5) 1 (6) Letters to the Editor molecular panel, are enriched within CMML patients and also frequently co-occur with IDH2 mutations, the IDH2/CMML association may be related to underlying SRSF2 co-mutations. 13, 14 Notably also, no patients with the WHO classification of MDS with refractory anemia (RA) were IDH1/2-mutated, although RA patients comprised 9% of the total MDS cohort. The frequency of other somatic mutations among IDH1/2-mutated versus wild-type patients is displayed in Table 1 . No IDH1/2-mutated MDS patient also had a TP53 mutation at presentation, compared to 17% of the IDH1/2 wild-type MDS cohort (P = 0.006). While rare overall, no IDH1/2-mutated patients had concomitant FLT3-ITD or FLT3-D835 mutation (0 vs 2%, P = 0.006). Patients with IDH1/2 mutations were also significantly less likely to have a RUNX1 (13 vs 40%, P = 0.015), ASXL1 (21 vs 44%, P = 0.039), or TET2 mutation (8 vs 35%, P = 0.008). While TET2 mutations are frequently thought to be mutually exclusive with IDH1/2 mutations, 2 patients with IDH2-R140 mutations did have concurrent TET2 mutations identified. While the subsets are small, the distribution of KRAS, NRAS, JAK2, NPM1, DNMT3A, EZH2 and CEBPA mutations were similar between IDH1/2-mutated and wildtype patients.
OS among the 701 treatment-naïve MDS patients (including 45 IDH1/2-mutants) was 21.2 months; 22.2 months for IDH1/2-mutated patients and 21.1 months for IDH1/2 wild-type patients (P = 0.67). [ Figure 1 ] Within IDH1/2 mutants, survival was not different based on IDH1 vs IDH2 mutation status; 22.2 months for IDH1 and 21.0 months for IDH2 mutants (P = 0.44). Progressionfree survival for treatment-naive MDS patients was 19.9 months (range 0-47.4 months); 22.2 months for IDH1/2-mutated and 19.7 months for IDH1/2 wild-type (P = 0.77). Progression-free survival among patients with IDH mutations was similar, 16.9 months in IDH1-mutated patients and 17.4 months IDH2-mutated patients (P = 0.18).
Of the 214 treatment-naive patients receiving HMA therapy for which response assessments are available, 18 (8.4%) had IDH1/2 mutations (Supplementary Table 1 ). No significant difference in the rate of responses was seen based on the presence of IDH1/2 mutations, with complete remission (CR) in 7 out of 18 IDH1/2-mutant (39%) versus 63 out of 196 (32%) IDH wild-type patients (P = 0.56). OS was similarly not dependent on IDH1/2-mutation status in this HMA-treated group, with a median OS of 20.0 months in IDH1/2-mutant patients and 15.0 months in IDH wild-type patients, P = 0.64 (Supplementary Figure 1) .
During the treatment course of the complete n = 1042 cohort, 150 MDS patients transformed to AML. This includes 11 out of the 60 patients with IDH1/2-mutation identified at MDS diagnosis (1 IDH1 and 10 IDH2; 18% of IDH1/2-mutated patients), and 138 (14%) IDH1/2 wild-type MDS patients. In addition, seven confirmed IDH1/2 wild-type patients at MDS diagnosis had an identified IDH1 or IDH2 mutation at the time of AML transformation (n = 5) or progression to RAEB-2 MDS (n = 2; one subsequently progressed to AML within another 6 weeks), with an allelic frequency ranging from 10-37%. Specific details of these seven patients are provided in Table 2 . Of interest, patient #5 had both an IDH1-R132H and IDH2-R140Q mutation at the time of AML transformation. In the patients with apparent IDH1/2 acquisition, IDH1/2 mutations were detected a median of 1.3 years from original presentation, at the time of disease progression. In these seven patients, OS was universally poor, with 3 month median OS from time of IDH1/2 detection. Thus of the 150 MDS patients transforming to AML, 17 (11.3%) were identified to have an IDH1/2-mutation at the time of AML progression.
We acknowledge several study limitations. Given the limits of sequencing technology, we cannot fully rule out the presence of a small IDH1/2 clone in some MDS patients at presentation, undetected at diagnosis which increased in size at the time of progression, thus more accurately representing clonal expansion rather than molecular acquisition. Additionally, selection bias, including more frequent molecular testing among MDS patients with transformation and proliferative disease in this retrospective study may have exaggerated the overall frequency of IDH1/2 acquisition. However this is unlikely the case, as only 42 out of 150 (28%) MDS patients transforming to AML had repeated comprehensive molecular sequencing performed within 8 weeks of transformation, and thus the frequency of IDH1/2 acquisition or expansion, particularly in MDS patients with diploid or intermediate cytogenetics, may be even higher than reported.
We have previously reported on the dynamic acquisition of FLT3 and RAS mutations in lower-risk patients at the time of MDS disease progression, 15 specifically in 20 out of 278 IPSS low or intermediate-1 risk MDS patients, of whom 18 (90%) then transformed to AML. Our findings suggest we can also consider IDH1/2 mutations as molecular 'drivers' of leukemic transformation in some MDS patients. It will be most interesting to evaluate the efficacy of targeted IDH-inhibitors in the secondary/transformed AML setting, specifically whether responding patients revert back to a prior MDS state, or whether complete remissions with full count recovery are attainable. This further advocates a role for rational combination studies of IDH-inhibitors with other effective MDS strategies such as hypomethylating agents for these patients.
To conclude, IDH1/2 mutations were found in 5.7% of MDS patients at presentation; 1.6% IDH1-R132 and 4.1% IDH2-mutated. Only one MDS patient with an IDH2-R172 mutation was identified, the IDH2-R140 mutation comprised all other IDH2 mutants. The notable low frequency of IDH1-R132 and IDH2-R172 mutations is consistent with recent data by Molenaar et al., 10 suggesting IDH1-R132 and IDH2-R172 mutations are less frequently involved in the ancestral neoplastic clone. IDH1/2 mutations occurred more frequently in patients with diploid or other intermediate-risk cytogenetics and RAEB classification by WHO, and were less frequent in patients with TP53, RUNX1, ASXL1 or TET2 mutations. At the time of leukemic transformation/secondary AML, 11.3% of MDS patients had an IDH1/2-mutation identified, suggesting the importance of molecular profiling at the time of progression for optimal characterization and treatment decisions for our patients. Letters to the Editor
